Global Markets Direct: Market Research Reports

... releases. The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

... also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with ...

... releases. The Hemorrhage (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemorrhage and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

... . The Nasal Polyposis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... . The Skin And Soft Tissue Infections (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Skin And Soft Tissue Infections and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

... Galectin 1 (14 kDa Laminin Binding Protein or 14 kDa Lectin or Beta Galactoside Binding Lectin L 14 I or Galaptin or HBL or HPL or Lactose Binding Lectin 1 or Lectin Galactoside Binding Soluble 1 or Putative MAPK Activating Protein PM12 or S Lac Lectin 1 or LGALS1) targeted therapeutics under development ...

... Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Pipeline Review, H2 2017 Summary Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Tissue ...

... Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) - Pipeline Review, H2 2017 Summary Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed ...

... pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology), complete with analysis by stage of development ...

... pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency ...

... therapeutic landscape for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) The report reviews Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics under development ...

... Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB or EC 3.4.21.79) - Pipeline Review, H1 2017 SUMMARY Granzyme B (C11 or CTLA 1 or Cathepsin G Like 1 or Cytotoxic T Lymphocyte Proteinase 2 or Fragmentin 2 or Granzyme 2 or Human Lymphocyte Protein or SECT or T Cell Serine Protease 1-3E or GZMB ...

... pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Exocrine Pancreatic Insufficiency (Gastrointestinal), complete with analysis by stage of development ...

... pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System), complete with analysis by stage of development ...

... Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Bromodomain-containing protein 3 (BRD3) or RING3-like protein ...

Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017 SUMMARY According to the recently published report 'Human Papillomavirus Minor Capsid Protein L2 (L2) - Pipeline Review, H1 2017'; Human Papillomavirus Minor Capsid Protein L2 (L2) pipeline ...

... or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Pipeline Review, H1 2017 SUMMARY Mitogen Activated Protein Kinase 9 (c Jun N Terminal Kinase 2 or JNK 55 or Stress Activated Protein Kinase JNK2 or Stress Activated Protein Kinase 1a or MAPK9 or EC 2.7.11.24) - Mitogen-activated protein kinase ...

... developed by companies and remaining by the universities/institutes. Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 7 is an enzyme that is encoded by the MAP3K7 ...

... Mucopolysaccharidosis I (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Mucopolysaccharidosis III (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development ...

... therapeutic landscape for TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) The report reviews TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics under development ...

... therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)targeted therapeutics under development ...

... pipeline guide Brain Ischemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Brain Ischemia (Central Nervous System), complete with analysis by stage of development ...

... pipeline guide Melasma (Chlosma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melasma (Chlosma) (Dermatology), complete with analysis by stage of development ...

... Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed ...

... Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Chagas Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Acid Sphingomyelinase Deficiency Type C (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Leber Congenital Amaurosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Leber Congenital Amaurosis (LCA) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

... pipeline guide Liver Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development ...

... pipeline guide Cachexia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cachexia (Musculoskeletal Disorders), complete with analysis by stage of development ...

... pipeline guide Fibrosis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Fibrosis (Musculoskeletal Disorders), complete with analysis by stage of development ...

... pipeline guide Dupuytren Contracture – Pipeline Review, H1 2017, provides an overview of the Dupuytren Contracture (Musculoskeletal Disorders) pipeline landscape. Dupuytren contracture is a hand deformity that usually develops slowly, over decades. Dupuytren contracture affects the connective tissue under ...

... hepatic colorectal metastases. REPORT HIGHLIGHTS Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatic - Colorectal Metastasis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatic - Colorectal Metastasis ...

... pipeline guide Hemorrhage - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemorrhage (Hematological Disorders), complete with analysis by stage of development ...

... pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H1 2017, provides an overview of the Skin And Soft Tissue Infections (Dermatology) pipeline landscape. Skin and soft tissue infections are infections involving the layers of the skin and the soft tissues ...

... pipeline guide Hypotension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypotension (Cardiovascular), complete with analysis by stage of development ...